Evaxion Biotech A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
0.920
+0.030 (3.36%)
Dec 20, 2024, 4:00 PM EST - Market closed
Evaxion Biotech Stock Forecast
EVAX's stock price has decreased by -85.21% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Evaxion Biotech stock have an average target of 11, with a low estimate of 8.00 and a high estimate of 14. The average target predicts an increase of 1,095.65% from the current stock price of 0.92.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 1, 2024.
Analyst Ratings
The average analyst rating for EVAX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +1,421.74% | Nov 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +1,421.74% | Sep 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +1,421.74% | Sep 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +1,421.74% | Aug 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +1,421.74% | Aug 1, 2024 |
Financial Forecast
Revenue This Year
3.61M
from 73.00K
Increased by 4,845.21%
Revenue Next Year
4.70M
from 3.61M
Increased by 30.30%
EPS This Year
-1.34
from -8.09
EPS Next Year
-1.29
from -1.34
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 6.9M | 13.9M | 85.2M | |||
| Avg | 3.6M | 4.7M | 54.9M | |||
| Low | 527,240 | n/a | 26.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 9,308.2% | 286.1% | 1,710.9% | |||
| Avg | 4,845.2% | 30.3% | 1,067.4% | |||
| Low | 622.2% | - | 453.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.17 | -0.16 | 0.08 | |||
| Avg | -1.34 | -1.29 | 0.08 | |||
| Low | -2.41 | -3.34 | 0.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.